{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:04Z","timestamp":1786119544798,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/01.hjh.0000388496.66330.b8","type":"journal-article","created":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T15:30:29Z","timestamp":1283527829000},"page":"S56-S61","source":"Crossref","is-referenced-by-count":19,"title":["Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors"],"prefix":"10.1097","volume":"28","author":[{"given":"Gema","family":"Ruiz-Hurtado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210208","first-page":"56","article-title":"Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets","volume":"22","author":"Diwan","year":"2007","journal-title":"Physiology (Bethesda)"},{"key":"R2-10-20210208","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000175819","article-title":"Left ventricular hypertrophy and mortality \u2013 results from the Framingham Study","volume":"81","author":"Kannel","year":"1992","journal-title":"Cardiology"},{"key":"R3-10-20210208","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"R4-10-20210208","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.phrs.2009.11.012","article-title":"Molecular targets and regulators of cardiac hypertrophy","volume":"61","author":"Rohini","year":"2010","journal-title":"Pharmacol Res"},{"key":"R5-10-20210208","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cbpb.2005.05.048","article-title":"Regulation of the mammalian heart function by nitric oxide","volume":"142","author":"Massion","year":"2005","journal-title":"Comp Biochem Physiol A Mol Integr Physiol"},{"key":"R6-10-20210208","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.HYP.27.1.14","article-title":"Chronic l-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats","volume":"27","author":"Matsuoka","year":"1996","journal-title":"Hypertension"},{"key":"R7-10-20210208","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1742-7843.2008.00261.x","article-title":"L-Arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways","volume":"103","author":"Lin","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R8-10-20210208","doi-asserted-by":"crossref","first-page":"E1131","DOI":"10.1152\/ajpendo.00107.2010","article-title":"l-Arginine restores endothelial nitric oxide synthase coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats.","volume":"298","author":"Ou","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R9-10-20210208","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1365-2362.2005.01507.x","article-title":"L-Arginine fails to protect against myocardial remodelling in L-name-induced hypertension","volume":"35","author":"Simko","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"R10-10-20210208","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajh.2008.334","article-title":"L-Arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat","volume":"22","author":"Brooks","year":"2009","journal-title":"Am J Hypertens"},{"key":"R11-10-20210208","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.295.1.58","article-title":"L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial","volume":"295","author":"Schulman","year":"2006","journal-title":"JAMA"},{"key":"R13-10-20210208","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI21968","article-title":"Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load","volume":"115","author":"Takimoto","year":"2005","journal-title":"J Clin Invest"},{"key":"R14-10-20210208","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/CIRCULATIONAHA.107.737031","article-title":"Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy","volume":"117","author":"Moens","year":"2008","journal-title":"Circulation"},{"key":"R15-10-20210208","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCULATIONAHA.109.883777","article-title":"Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction","volume":"121","author":"Silberman","year":"2010","journal-title":"Circulation"},{"key":"R16-10-20210208","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cardiores.2005.01.021","article-title":"Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload","volume":"66","author":"Ruetten","year":"2005","journal-title":"Cardiovasc Res"},{"key":"R17-10-20210208","doi-asserted-by":"crossref","first-page":"H1070","DOI":"10.1152\/ajpheart.00940.2003","article-title":"Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency","volume":"286","author":"Ichinose","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R18-10-20210208","doi-asserted-by":"crossref","first-page":"H620","DOI":"10.1152\/ajpheart.01236.2006","article-title":"Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload","volume":"293","author":"Buys","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R19-10-20210208","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/CIRCULATIONAHA.107.717702","article-title":"Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction","volume":"118","author":"Fraccarollo","year":"2008","journal-title":"Circulation"},{"key":"R20-10-20210208","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00395-009-0014-6","article-title":"Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure","volume":"104","author":"Westermann","year":"2009","journal-title":"Basic Res Cardiol"},{"key":"R21-10-20210208","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1161\/CIRCULATIONAHA.105.539437","article-title":"Nnos gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction","volume":"112","author":"Dawson","year":"2005","journal-title":"Circulation"},{"key":"R22-10-20210208","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1161\/CIRCULATIONAHA.105.557892","article-title":"Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium","volume":"112","author":"Saraiva","year":"2005","journal-title":"Circulation"},{"key":"R23-10-20210208","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1161\/CIRCULATIONAHA.107.741702","article-title":"Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling","volume":"117","author":"Loyer","year":"2008","journal-title":"Circulation"},{"key":"R24-10-20210208","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0022-2828(03)00079-8","article-title":"Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice","volume":"35","author":"Barouch","year":"2003","journal-title":"J Mol Cell Cardiol"},{"key":"R25-10-20210208","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0008-6363(02)00676-4","article-title":"Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats","volume":"57","author":"Piech","year":"2003","journal-title":"Cardiovasc Res"},{"key":"R26-10-20210208","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1161\/HYPERTENSIONAHA.107.093666","article-title":"La419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation","volume":"50","author":"Ruiz-Hurtado","year":"2007","journal-title":"Hypertension"},{"key":"R27-10-20210208","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.RES.0000264081.78659.45","article-title":"Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure","volume":"100","author":"Zhang","year":"2007","journal-title":"Circ Res"},{"key":"R28-10-20210208","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/HYPERTENSIONAHA.108.121822","article-title":"Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension","volume":"53","author":"Sun","year":"2009","journal-title":"Hypertension"},{"key":"R29-10-20210208","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pharmthera.2009.08.001","article-title":"Exploiting cgmp-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond","volume":"124","author":"Ritchie","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R30-10-20210208","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/01.RES.0000103311.52853.48","article-title":"Regulation of gene expression by cyclic GMP","volume":"93","author":"Pilz","year":"2003","journal-title":"Circ Res"},{"key":"R31-10-20210208","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R32-10-20210208","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R33-10-20210208","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators.","volume":"191","author":"Schmidt","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"R34-10-20210208","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjp.0706792","article-title":"NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5\/6 nephrectomy","volume":"148","author":"Kalk","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R35-10-20210208","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"R36-10-20210208","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5a prevents and reverses cardiac hypertrophy","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat Med"},{"key":"R37-10-20210208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jacc.2008.08.069","article-title":"Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with preexisting advanced hypertrophy caused by pressure overload","volume":"53","author":"Nagayama","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R38-10-20210208","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.cellsig.2008.08.012","article-title":"Expression, activity, and pro-hypertrophic effects of PDE5a in cardiac myocytes","volume":"20","author":"Zhang","year":"2008","journal-title":"Cell Signal"},{"key":"R39-10-20210208","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCULATIONAHA.108.822072","article-title":"Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice","volume":"119","author":"Pokreisz","year":"2009","journal-title":"Circulation"},{"key":"R40-10-20210208","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.2174\/138161209789206953","article-title":"Phosphodiesterase-5 inhibitors: future perspectives","volume":"15","author":"Konstantinos","year":"2009","journal-title":"Curr Pharm Des"},{"key":"R41-10-20210208","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0008-6363(99)00091-7","article-title":"Interactions among ACE, kinins and NO","volume":"43","author":"Linz","year":"1999","journal-title":"Cardiovasc Res"},{"key":"R42-10-20210208","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.HYP.37.6.1450","article-title":"HMG-COA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species","volume":"37","author":"Wassmann","year":"2001","journal-title":"Hypertension"},{"key":"R43-10-20210208","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2362.2007.01837.x","article-title":"Statins: a perspective for left ventricular hypertrophy treatment","volume":"37","author":"Simko","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"R44-10-20210208","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FJC.0b013e31817751a7","article-title":"Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors","volume":"51","author":"Galderisi","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"R45-10-20210208","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1161\/01.CIR.97.20.2017","article-title":"Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial","volume":"97","author":"Mahmarian","year":"1998","journal-title":"Circulation"},{"key":"R46-10-20210208","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/01.CIR.99.18.2396","article-title":"Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy","volume":"99","author":"Matter","year":"1999","journal-title":"Circulation"},{"key":"R47-10-20210208","first-page":"276","article-title":"La-419, a nitric-oxide donor for the treatment of cardiovascular disorders","volume":"10","author":"Megson","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"R48-10-20210208","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2005.04.040","article-title":"Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension","volume":"46","author":"Perticone","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R49-10-20210208","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/HYPERTENSIONAHA.107.100032","article-title":"La419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling","volume":"50","author":"Paulis","year":"2007","journal-title":"Hypertension"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004872-201009001-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:32:33Z","timestamp":1786041153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-201009001-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":48,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/01.hjh.0000388496.66330.b8","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}